Analysts Set Jasper Therapeutics, Inc. (NASDAQ:JSPR) Price Target at $73.38

Shares of Jasper Therapeutics, Inc. (NASDAQ:JSPR) have earned a consensus recommendation of “Buy” from the ten brokerages that are presently covering the firm, Marketbeat Ratings reports. Ten research analysts have rated the stock with a buy recommendation. The average 1 year price target among brokerages that have covered the stock in the last year is $73.38.

Several research analysts recently commented on the company. HC Wainwright reiterated a “buy” rating and issued a $65.00 price target on shares of Jasper Therapeutics in a research note on Thursday, October 24th. JMP Securities reiterated a “market outperform” rating and set a $70.00 target price on shares of Jasper Therapeutics in a research note on Tuesday, October 15th. BMO Capital Markets assumed coverage on shares of Jasper Therapeutics in a research note on Friday, December 6th. They issued an “outperform” rating and a $63.00 price target for the company. Cantor Fitzgerald reiterated an “overweight” rating on shares of Jasper Therapeutics in a research note on Monday, September 9th. Finally, Royal Bank of Canada reissued an “outperform” rating and set a $68.00 price objective on shares of Jasper Therapeutics in a report on Monday, December 23rd.

Hedge Funds Weigh In On Jasper Therapeutics

A number of hedge funds have recently added to or reduced their stakes in the business. BNP Paribas Financial Markets raised its holdings in shares of Jasper Therapeutics by 208.6% during the third quarter. BNP Paribas Financial Markets now owns 2,512 shares of the company’s stock worth $47,000 after purchasing an additional 1,698 shares during the period. Wolff Wiese Magana LLC bought a new stake in shares of Jasper Therapeutics during the 3rd quarter valued at about $59,000. MetLife Investment Management LLC raised its stake in Jasper Therapeutics by 129.1% during the third quarter. MetLife Investment Management LLC now owns 6,874 shares of the company’s stock worth $129,000 after acquiring an additional 3,873 shares during the period. Rhumbline Advisers bought a new position in Jasper Therapeutics in the second quarter worth about $300,000. Finally, Jane Street Group LLC bought a new position in Jasper Therapeutics in the third quarter worth about $251,000. Institutional investors and hedge funds own 79.85% of the company’s stock.

Jasper Therapeutics Price Performance

Shares of JSPR stock opened at $19.27 on Wednesday. The company’s fifty day moving average price is $22.07 and its two-hundred day moving average price is $20.50. The firm has a market capitalization of $289.07 million, a P/E ratio of -4.07 and a beta of 2.18. Jasper Therapeutics has a 12 month low of $6.50 and a 12 month high of $31.01.

Jasper Therapeutics Company Profile

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.